6BNS

STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide and Compound 25a AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.56 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.203 
  • R-Value Observed: 0.205 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (ROR gamma /RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.

Gong, H.Weinstein, D.S.Lu, Z.Duan, J.J.Stachura, S.Haque, L.Karmakar, A.Hemagiri, H.Raut, D.K.Gupta, A.K.Khan, J.Camac, D.Sack, J.S.Pudzianowski, A.Wu, D.R.Yarde, M.Shen, D.R.Borowski, V.Xie, J.H.Sun, H.D'Arienzo, C.Dabros, M.Galella, M.A.Wang, F.Weigelt, C.A.Zhao, Q.Foster, W.Somerville, J.E.Salter-Cid, L.M.Barrish, J.C.Carter, P.H.Dhar, T.G.M.

(2018) Bioorg Med Chem Lett 28: 85-93

  • DOI: 10.1016/j.bmcl.2017.12.006
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (P ...

    We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Y max in the PXR assay for long term preclinical pharmacokinetic (PK) studies.


    Organizational Affiliation

    Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States. Electronic address: murali.dhar@bms.com.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Nuclear receptor subfamily 1 group I member 2,Nuclear receptor coactivator 1 Chimera
A, B
351Homo sapiensMutation(s): 0 
Gene Names: NR1I2PXR
EC: 2.3.1.48
Find proteins for Q15788 (Homo sapiens)
Go to UniProtKB:  Q15788
NIH Common Fund Data Resources
PHAROS  Q15788
Find proteins for O75469 (Homo sapiens)
Go to UniProtKB:  O75469
NIH Common Fund Data Resources
PHAROS  O75469
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
XGH
Query on XGH

Download CCD File 
A, B
2-[(2S)-4-[(4-fluorophenyl)sulfonyl]-7-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-(2-hydroxy-2-methylpropyl)acetamide
C23 H23 F7 N2 O5 S2
XUCORPNQMQOUMD-HNNXBMFYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.56 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.203 
  • R-Value Observed: 0.205 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 84.37α = 90
b = 89.234β = 90
c = 105.902γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
PDB_EXTRACTdata extraction
DENZOdata reduction
SCALEPACKdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Revision History 

  • Version 1.0: 2017-12-20
    Type: Initial release
  • Version 1.1: 2017-12-27
    Changes: Database references
  • Version 1.2: 2018-01-03
    Changes: Database references